7.15
0.00%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Agenus
From its filings with the US Securities and Exchange Commission
Agenus is based in Lexington, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker AGEN. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $114.2m and a net loss of $3.1m. At that date it held total assets of $226.8m and shareholders' equity of −$271.1m. By region, United States [Member] accounted for 99.1%, followed by Rest of World [Member] at 0.9%.
Agenus is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious disease. Our primary business is immuno-oncology ("I-O"), where we are advancing antibody-based programs to activate innate and adaptive immunity, overcome tumor immune evasion and expand the population of patients who may benefit from immunotherapy. Our lead clinical program is botensilimab (“BOT” or “AGEN1181”), alone and in combination with balstilimab (“BAL”). We also maintain select clinical-stage immuno-oncology assets, which may be used as standalone agents or be complimentary to botensilimab plus balstilimab (“BOT/BAL”). Agenus also maintains an equity investment in MiNK Therapeutics, Inc. ("MiNK"), with an approximate fair value of $24.3 million as of December 31, 2025, and a majority ownership of a vaccine adjuvant business through our subsidiary SaponiQx, Inc. ("SaponiQx").
Our strategy is to focus capital on execution of programs that we believe have the clearest path to meaningful clinical and commercial value, led by BOT/BAL in colorectal cancer and selected other tumor types. We intend to advance late-stage development and support responsible paid patient access programs as well as clinical trials. We maintain manufacturing flexibility through strategic collaborations with an emphasis on our Zydus collaboration.
Quoted from its 10-K, filed 16 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 4 Feb 2000
- Employees
- 81
- Website
- agenusbio.com ↗
- Head office
- 3 FORBES ROAD, LEXINGTON, MA, 02421
- Incorporated in
- DE
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. Garo ArmenChairman of the Board, Chief Executive Officer, Co-Founder, since 1994$3.7m
- Ms. Christine KlaskinVice President - Finance$483,477
- Mr. Richard GoldbergChief Development Officer
- Dr. Steven O'DayChief Medical Officer$968,491
- Mr. Timothy WrightLead Independent Director$232,883
- Dr. Jennifer BuellDirector, since 2018$7.4m
- Mr. Brian CorveseIndependent Director$490,308
- Mr. Thomas HarrisonIndependent Director$64,677
- Ms. Susan HirschIndependent Director$138,950
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 36
- Environment
- 15
- Social
- 65
- Governance
- 29
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Agenus Inc develops clinical-stage immuno-oncology technologies for cancer treatment in the US Health Care sector.
- Agenus focuses on antibody discovery platforms like Retrocyte Display and SECANT yeast display in biotechnology.
- Agenus Inc's vaccine programs include Prophage, AutoSynVax, and PhosPhoSynVax for infectious diseases.
Weaknesses
- Agenus Inc has 81 employees, which is lower than the industry average for biotechnology companies.
- Agenus Inc's headquarters in Lexington, Massachusetts, is not a major biotech hub like Boston.
- Agenus Inc's IPO in 2000 is over 20 years old, indicating limited recent market activity.
Opportunities
- Agenus Inc can expand its vaccine programs into the global market for infectious diseases.
- Agenus Inc's antibody discovery platforms can be licensed to other biotech firms for revenue generation.
- Agenus Inc's checkpoint modulator programs may attract partnerships with larger pharmaceutical companies.
Threats
- Agenus Inc faces competition from established biotech companies in the US Health Care sector.
- Agenus Inc's reliance on a single platform, QS-21 Stimulon adjuvant, poses a risk to its vaccine programs.
- Agenus Inc's clinical-stage development requires significant funding, which may be challenging to secure.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.